NCT05567835 2026-02-23
TOGAR
Baylor College of Medicine
Phase 2 Terminated
Clinical Trials
16 trialsNCT02724202 2026-02-06
Curcumin in Combination With 5FU for Colon Cancer
Baylor Research Institute
Phase EARLY_PHASE1 Terminated
NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
NCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT02688803 2025-12-04
OTT15-04
Ottawa Hospital Research Institute
Phase 4 Terminated
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT04141995 2025-08-07
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
Phase 2 Terminated
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT02420509 2025-06-04
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated